Presenter Status
Medical Student
Abstract Type
Clinical Research
Primary Mentor or Principal Investigator
Laura Ramsey, PhD
Presentation Type
Poster-Restricted Access
Start Date
21-5-2026 12:00 PM
End Date
21-5-2026 1:00 PM
Abstract Text
Background: The GOLDILOKs® (Genomic and Ontogeny-Linked Dose Individualization and Clinical Optimization for Kids) Clinic provides personalized care for children receiving pharmacologic therapy.1 Since opening in July 2010, clinic providers have offered genotype informed clinical guidance to pediatric patients and their healthcare providers. However, no comprehensive retrospective study has specifically examined psychiatric conditions to evaluate how frequently and effectively this clinical guidance is utilized by providers.
Objectives/Goal: The objectives are two-fold: (1) to evaluate the clinical guidance provided by the GOLDILOKs Clinic, and (2) to assess the utilization and implementation of these recommendations in patient treatment.
Methods/Design: Patient data was retrospectively reviewed from July 2010 to January 2026 following Institutional Review Board (IRB) approval. To date, 196 of 794 patients seen in the clinic have been reviewed. This study focused on patients < 18 years old presenting for psychiatric medication recommendations. Eligible patients were screened for psychiatric conditions and included if they completed their clinic appointments, during which GOLDILOKs® providers issued pharmacogenetic informed recommendations regarding medication regimens. Electronic health records were reviewed for one year after their GOLDILOKs® appointment to determine whether providers adjusted medication regimens in accordance with clinic recommendations. Data was collected using REDCap to ensure standardized and consistent data capture. Of the 196 patients evaluated, 113 met inclusion criteria for this study, including presentation for psychiatric medication recommendations and fulfillment of age and follow-up requirements.
Results: The most common psychiatric diagnoses seen by the GOLDILOKs® Clinic were anxiety disorders (72 patients, 63.7%) and neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), (64 patients, 74.4%). The most common recommendations involved selective serotonin reuptake inhibitors (SSRIs), with 52 patients (46%) receiving an SSRI-related recommendation. This was followed by cases in which no recommendation was made (23 patients, 20.4%) and ADHD-related recommendations (22 patients, 19.5%).
Within one year of their GOLDILOKs® appointment, 42 patients (46%) with documented recommendations were seen by their provider. Among patients who received SSRI recommendations and were seen within one year by their provider (n=22), 14 (63.6%) had medication changes implemented in alignment with GOLDILOKs® clinical guidance. A similar pattern was observed among patients with ADHD-related recommendations (n=14), with 9 patients (64.3%) having medication regimens adjusted in accordance with clinic guidance. Comparable trends were also noted for serotonin–norepinephrine reuptake inhibitor (SNRI) recommendations (6 of 11 patients, 54.5%) and mood stabilizers (8 of 16 patients, 50%).
Conclusions: Pharmacogenetic guided recommendations from the GOLDILOKs® Clinic are frequently incorporated into psychiatric medication management when patients follow up with their providers. The observed rates of implementation, particularly for SSRI and ADHD related recommendations, suggest that genotype informed guidance can play a meaningful role in clinical decision making. As this is an ongoing project, continued data entry and analysis will further clarify utilization patterns and the clinical impact of pharmacogenetic recommendations in pediatric psychiatric care.
From Recommendation to Practice: Evaluating Utilization of the GOLDILOKS Clinic Clinical Guidance in Psychiatric Conditions
Background: The GOLDILOKs® (Genomic and Ontogeny-Linked Dose Individualization and Clinical Optimization for Kids) Clinic provides personalized care for children receiving pharmacologic therapy.1 Since opening in July 2010, clinic providers have offered genotype informed clinical guidance to pediatric patients and their healthcare providers. However, no comprehensive retrospective study has specifically examined psychiatric conditions to evaluate how frequently and effectively this clinical guidance is utilized by providers.
Objectives/Goal: The objectives are two-fold: (1) to evaluate the clinical guidance provided by the GOLDILOKs Clinic, and (2) to assess the utilization and implementation of these recommendations in patient treatment.
Methods/Design: Patient data was retrospectively reviewed from July 2010 to January 2026 following Institutional Review Board (IRB) approval. To date, 196 of 794 patients seen in the clinic have been reviewed. This study focused on patients < 18 years old presenting for psychiatric medication recommendations. Eligible patients were screened for psychiatric conditions and included if they completed their clinic appointments, during which GOLDILOKs® providers issued pharmacogenetic informed recommendations regarding medication regimens. Electronic health records were reviewed for one year after their GOLDILOKs® appointment to determine whether providers adjusted medication regimens in accordance with clinic recommendations. Data was collected using REDCap to ensure standardized and consistent data capture. Of the 196 patients evaluated, 113 met inclusion criteria for this study, including presentation for psychiatric medication recommendations and fulfillment of age and follow-up requirements.
Results: The most common psychiatric diagnoses seen by the GOLDILOKs® Clinic were anxiety disorders (72 patients, 63.7%) and neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), (64 patients, 74.4%). The most common recommendations involved selective serotonin reuptake inhibitors (SSRIs), with 52 patients (46%) receiving an SSRI-related recommendation. This was followed by cases in which no recommendation was made (23 patients, 20.4%) and ADHD-related recommendations (22 patients, 19.5%).
Within one year of their GOLDILOKs® appointment, 42 patients (46%) with documented recommendations were seen by their provider. Among patients who received SSRI recommendations and were seen within one year by their provider (n=22), 14 (63.6%) had medication changes implemented in alignment with GOLDILOKs® clinical guidance. A similar pattern was observed among patients with ADHD-related recommendations (n=14), with 9 patients (64.3%) having medication regimens adjusted in accordance with clinic guidance. Comparable trends were also noted for serotonin–norepinephrine reuptake inhibitor (SNRI) recommendations (6 of 11 patients, 54.5%) and mood stabilizers (8 of 16 patients, 50%).
Conclusions: Pharmacogenetic guided recommendations from the GOLDILOKs® Clinic are frequently incorporated into psychiatric medication management when patients follow up with their providers. The observed rates of implementation, particularly for SSRI and ADHD related recommendations, suggest that genotype informed guidance can play a meaningful role in clinical decision making. As this is an ongoing project, continued data entry and analysis will further clarify utilization patterns and the clinical impact of pharmacogenetic recommendations in pediatric psychiatric care.
Comments
Poster Board Number: 26